UK scientists have begun testing a new method of treating coronavirus infection with antibodies. If it proves effective, then those infected with SARS-CoV-2 will receive protection against the progression of COVID-19, reports Science Alert.
The drug AZD7442 was created by specialists from University College London Hospital and AstraZeneca. It is a combination of monoclonal antibodies AZD8895 and AZD1061 targeting the receptor-binding domain of the SARS-CoV-2 spike protein. By attaching to this part of the coronavirus protein, antibodies block the attachment of the virus to the cell and its further penetration into it.
Scientists have made changes to antibodies that increase their duration of action (up to 6-12 months), and also reduce the risk of antibody-dependent aggravation of the disease. The researchers hope this will help people exposed to the coronavirus avoid developing symptoms of COVID-19. Such prevention will, for example, save the lives of elderly people who are in nursing homes.